April 3, 2020 09:33 AM EDTUpdated 11:46 AM
Financing
Bioregnum
Opinion

A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

How could a small, large­ly un­known biotech that emerged from stealth mode just months ago with ear­ly-stage can­cer pro­grams jump on­to Wall Street in the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

A service from the Financial Times